within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDiseaseGord.A02BX10_Zolimidine;

model Zolimidine
  extends Pharmacolibrary.Drugs.ATC.A.A02BX10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A02BX10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Zolimidine is a substituted benzamidine formerly used as a gastric acid secretion inhibitor in the treatment of peptic ulcers and related gastrointestinal disorders. It is not currently approved or widely used in modern clinical practice.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult, healthy subjects for oral administration as no published studies reporting human PK parameters were found.</p><h4>References</h4><ol><li><p>Schraven, E, &amp; Trottnow, D (1976). [The pharmacokinetics of 14C-zolimidine in rats]. <i>Arzneimittel-Forschung</i> 26(2) 213–218. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/947201/&quot;>https://pubmed.ncbi.nlm.nih.gov/947201</a></p></li><li><p>Almirante, L, et al., &amp; Cattaneo, R (1974). Metabolic fate of Zolimidine. I. Studies in rats with the 14-C-labelled molecule. <i>Il Farmaco; edizione scientifica</i> 29(11) 841–847. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4442572/&quot;>https://pubmed.ncbi.nlm.nih.gov/4442572</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Zolimidine;
